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No Evidence for Association between Tyrosine Hydroxylase 
Gene Val81Met Polymorphism and Susceptibility to 
Tardive Dyskinesia in Schizophrenia 
 
 
 
ObjectiveaaTyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis. 
Because the TH Val81Met polymorphism is located in the amino-terminal regulatory domain 
of the tetrameric enzyme, it is a candidate marker for susceptibility to dopamine-related traits. 
We investigated the hypothesis that TH Val81Met polymorphism can influence susceptibil-
ity to tardive dyskinesia (TD) in schizophrenia. 
MethodsaaTH Val81Met polymorphism was analyzed by PCR-based methods in 83 schizo-
phrenic patients with TD and 126 schizophrenic patients without TD, matched for antipsy-
chotic drug exposure and other relevant variables. 
ResultsaaThere was no significant association of the genotype and allele frequencies deter-
mined by the TH Val81Met polymorphism between TD and non-TD patients. In addition, 
there was no significant difference in terms of total Abnormal Involuntary Movement Scale 
scores among the three genotype groups. 
ConclusionaaWithin the limitations imposed by the size of the clinical sample, these findings 
suggest that the Val81Met polymorphism of the TH gene does not contribute significantly to 
the risk for TD. 
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Introduction 
 
Tardive dyaskinesia (TD) is one of the most serious adverse effects of neuroleptics. 
The typical symptoms of TD are involuntary movements of the orofacial musculature, 
trunk and extremities. Given that only a small proportion of those treated with neuro-
leptics develops TD, individual vulnerabilities such as genetic predisposition are im-
portant. Genetic vulnerability to the development of TD has been suggested based on
the results of studies in both animals
1 and families.
2 Several biological mechanisms of
TD have been hypothesized, including dopamine receptor supersensitivity,
3 gamma-
aminobutyric acid insufficiency,
4 and oxidative stress.
5 However, the pathophysiology 
of TD is not well understood. 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis.
6,7 
The Val81Met polymorphism of the TH gene is the most frequent known coding se-
quence variant located in the regulatory domain of the tetrameric enzyme.
8 Under phys-
iological conditions, the activity of TH is regulated by phosphorylation.
9 Phosphorylat-
ed TH has enhanced efficacy in dopamine synthesis. Antipsychotic drugs have been
reported to increase TH activity,
10 likely through increases of phosphorylated TH via 
binding to dopamine D2 receptors.
11 
Recently, alpha methyl paratyrosine (AMPT), an inhibitor of TH, has been reported 
to be clinically efficacious in the treatment of antipsychotic-induced TD.
12 Consequ- 
 
 
 
 
HJ Lee et al. 
www.psychiatryinvestigation.org 109 
ently, it has been suggested that the efficacy of AMPT in 
TD may be related to a downregulation of TH activity that 
may be increased by neuroleptic-induced effects on TH 
phosphorylation.
12 
Thus, functional polymorphism of TH can be regarded 
as one of the candidate markers for susceptibility to neuro-
leptic-induced TD. We investigated a possible association 
between Val81Met polymorphism in exon 3 of the TH gene 
and TD in a genetically homogenous Korean population. 
 
Methods  
 
Subjects and tardive dyskinesia assessment 
All subjects were examined by trained psychiatrists us-
ing the Korean version of the Structured Clinical Inter-
view for DSM-IV, leading to a diagnosis based on DSM-
IV criteria.
13 Written informed consents were obtained and 
the study protocol was approved by the Ethics Committee 
of the Korea University Medical Center. None of the pa-
tients had a significant comorbid neurological illness, men-
tal retardation or substance abuse, and all of them were 
inpatients at the three collaborating hospitals of Korea 
University hospital. Some findings from these subjects 
have been reported previously.
14-19 Identification of poten-
tial recruits to the study was made via assessment with 
the Abnormal Involuntary Movement Scale (AIMS); 83 
schizophrenic patients with TD were thus characterized.
20 
We included TD patients who had received atypical anti-
psychotics treatment (23 patients) and less than 10 years 
of treatment (18 patients) in our sample; however, all of 
the non-TD patients had received typical antipsychotic 
treatment for at least 10 years. Their current antipsychot-
ic dosages were converted to chlorpromazine equivalents. 
All patients were maintained on stable dosages of antipsy-
chotics for at least 3 months before the assessment of TD. 
Diagnosis of TD was made according to the Research Di-
agnostic Criteria for TD (RDC-TD) on the basis of AI-
MS.
21 To ensure consistency in the ratings of TD, all raters 
achieved an inter-rater reliability of >0.90 with the investi-
gator bearing overall responsibility for the TD assess-
ments, based on the same series of patients, before com-
mencing the study. We rated the first 7 items of the AIMS 
to determine the total AIMS score of the abnormal move-
ments. Subjects with two or more two-point ratings, or one 
or more three-point ratings, on the first seven items of the 
AIMS were diagnosed as having TD according to RDC-TD.   
 
Genotyping 
Blood samples (5-10 mL) were collected into ethylene-
diaminetetraacetic acid (EDTA), and genomic DNA was 
isolated using Accuprep Genomic DNA Extraction Kit (Bi-
oneer, Korea) according to standard procedures. Analy-
sis of genomic DNA was carried out using Polymerase 
Chain Reaction (PCR) and PCR-based Restriction frag-
ment length polymorphism (PCR-RFLP). PCR amplifica-
tion was performed with the forward primer 5’ -ATC CCC 
TGC CTC TGT GTG CCA T-3’ and the reverse primer 
5’ -TCA GGA ACT CAG CCC ACA CAG C-3’ , giving a 
404 base pair (bp) product. The PCR product was di-
gested by the restriction enzyme Nia III for approximately 
3 hours at 37℃, then the reaction mixture was analyzed by 
2% agarose gel electrophoresis to ensure correct amplifi-
cation of the DNA fragment.
22 Nia III cleaves the Met81 
allele into three fragments of 173, 140, 91 bp, and the 
Val81 allele into two fragments of 313, 91 bp. 
 
Statistical analyses 
The presence of Hardy-Weinberg equilibrium was test-
ed with the χ2 test for goodness of fit. The χ2-test was used 
to compare categorical data and differences for continuous 
variables were evaluated by using the Student’ s t-test or 
analysis of covariance (ANCOVA). The cutoff p value was 
set at 0.05. 
 
Results 
 
The genotype frequencies of Val81Met polymorphism of 
TH gene showed no significant deviation from the Hardy-
Weinberg equilibrium (χ2=0.46, p=0.50). There were no 
differences in age (46.82 vs. 44.20, t=1.91, p=0.058), sex 
distribution (M/F, 48/35 vs. 62/64, χ2=1.49, p=0.22), the 
duration of illness (19.58±8.57 years vs. 19.13±6.28 
years, t=0.39, p=0.70), and current antipsychotic dosage in 
chlorpromazine units (555.44±564.64 vs. 455.83±491.70, 
t=0.72, p=0.48) between TD and non-TD groups. However, 
the duration of antipsychotic treatment of the non-TD 
group was significantly longer than that of the TD group 
(17.56±5.66 years vs. 15.36±7.56 years, t=2.16, p=0.033). 
TABLE 1. Comparison of the tyrosine hydroxylase Val81Met polymorphism genotypes and allele frequencies between schizophrenia with 
TD and without TD 
 Genotypes    Allele frequencies 
 Met/Met  Met/Val  Val/Val      Met  Val   
Schizophrenia with TD (N=83) 50  30  3    0.78 0.22 
Schizophrenia without TD (N=126)  72 43 11 
χ2=2.10 
p=0.35    0.74 0.26 
χ2=0.92 
p=0.34 
TD: tardive dyskinesias  
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For genetic analysis, there was no significant difference 
of the TH genotype and allele frequencies between TD 
and non-TD patients (Table 1). Demographic character-
istics and the total AIMS scores according to the TH geno-
types were shown in Table 2. Comparison of the TD se-
verity among genotypes of TD patients using ANCOVA 
with sex, age, duration of antipsychotics and smoking 
status as covariates revealed no significant difference in the 
mean total AIMS scores of the different genotypes (F= 
1.24, p=0.30). 
 
Discussion 
 
Some studies indicate that conventional neuroleptics may 
exert a selective neuronal toxicity in the nigrostriatal do-
paminergic neurons, and this neurotoxity may underlie ex-
trapyramidal side effects of these drugs.
23 In agreement 
with this line of evidence, subchronic haloperidol treat-
ment reduced TH immunostaining in the striatum and caus-
ed shrinkage of the dopaminergic cell bodies in substantia 
nigra.
24 Lerner et al.
25 reported changes of TH Vmax (max-
imal transport capacity) after chronic haloperidol adminis-
tration and suggested an elevated TH protein expression 
by long-term haloperidol treatment. Recently, AMPT, an 
inhibitor of TH has been reported to be clinically effica-
cious for treating neuroleptic-induced TD.
12  
Albanese et al.
26 reported that allelic variations of the 
tetranucleotide microsatellite (TCAT) in the intron 1 of 
TH gene alter the functional activity of TH protein. Be-
cause the Val81Met polymorphism we have studied was 
in significant linkage disequilibrium with the TCAT poly-
morphism, it is also regarded as a functional polymor-
phism. Therefore, the Val81Met functional polymorphism 
of TH gene can be regarded as one of the candidate mark-
ers for genetic study of individual susceptibility to neuro-
leptic-induced TD.   
Allele frequencies in our sample were similar to those 
in other Asian samples.
27 However, in Caucasians the al-
lele frequencies were remarkably different, the Val allele 
being more frequent.
8 
Polymorphisms generating Val81 and Met81 were com-
pared to the distributions of genotype and allele between 
the schizophrenic patients with TD and without TD. These 
comparisons did not support an association between the 
polymorphism and neuroleptic-induced TD. These results 
indicate that Val81Met functional polymorphism of TH 
is not associated with neuroleptic-induced TD in Korean 
schizophrenic patients. 
There are several limitations to generalization of the re-
sults of this study. First, although anticholinergics and ben-
zodiazepines have been reported to be beneficial in some 
cases of TD, in this study we could not control for the pre-
scription of those drugs. Secondly, we cannot exclude pre-
sence of population stratification bias. However, we do 
not think that stratification bias should be considered se-
riously in our sample because the Korean population is 
characterized by a genetic homogeneity.
28 Third, the rel-
atively small sample size limits the generalizationabilty of 
our findings. Because our sample size is relatively small, 
our data cannot exclude the possibility that TH Val81Met 
polymorphism has an influence on susceptibility to TD.   
Taking these limitations into account, further investiga-
tions involving additional genes and markers and larger 
samples are warranted to fully understand the genetic path-
ophysiology of TD. 
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